NeoantigenPharmaceutical InformationUpdated on Jul 23, 2018 View more like this | Visit SHIRLEY, NY | Contact Cathy Miller |
Neoantigens is a class of HLA-bound peptides that arise from tumor-specific mutations. They are highly immunogenic because they are not present in normal tissues, thus can be used as biomarkers differentiating cancer cells from normal cells. It has been shown that recognition of these individual-specific neoantigens opens a new door for cancer immunotherapy.
Several clinical studies indicated that vaccination with neoantigens could both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients. Since these neoantigen peptides are patient specific, developing personalized vaccine would target cancer cells of an individual specifically and effectively.
Several clinical studies indicated that vaccination with neoantigens could both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients. Since these neoantigen peptides are patient specific, developing personalized vaccine would target cancer cells of an individual specifically and effectively.
